Abstract: The silica gel carrying a titanium oxide photocatalyst in a high concentration of the present invention is characterized in that the concentration of the titanium oxide contained in the pores near the surface of the silica gel is 7-70% by weight, said silica gel having an average pore diameter of 6-100 nm, provided that the concentration gradient is provided such that the amount of the titanium oxide contained in the pores near the surface of the silica gel is 1.5 times or more than the amount of the titanium oxide contained in the pores near the central part of the silica gel.

Abstract: A method of coating a catalyst to a support for use in acrolein oxidation reaction. Metallic salt components of the catalyst including molybdate, vanadate and tungstate are dissolved in a liquid to form a suspension of particles of the catalyst. The precipitation of the catalyst particles is controlled by homogenizing the catalyst particles suspended in the liquid. The phase separation between the catalyst particles and the liquid can be substantially slowed down by the homogenization. Then the catalyst is coated on an inert support by applying the suspension of the catalyst particles to the support. In the suspension, the total weight of water is about 0.8 to about 5 times of the total weight of the metallic salts in the catalyst. This method of preparing suspension minimizes the amount of the liquid required to dissolve the metallic salts, which reduces the amount of time and energy to be used in evaporating the liquid from the suspension.

Abstract: A method of checking the authenticity of a heat-sensitive recording material having a carrier paper with a recording layer which is arranged on one face and which contains colorant formers and organic colorant acceptors that react with one another when heated; and a security feature provided as a water-soluble dye which fluoresces under UV radiation, the dye being applied without binder in a pattern, invisible under daylight, to a surface of a face of the carrier paper opposite the face provided with the recording layer, so that the entire surface has the pattern, the water-soluble dye being applied at a mass per unit area between 0.01 and 40 mg/m2, the method comprising the step of wetting the surface of the layer opposite the recording layer with an alkaline substance.

Abstract: Composition and method for enhancing the moisture content of growing and cut trees and plants, including the steps of providing a polyacrylimide polymer in crystalline form, mixing salt with the polymer wherein the salt comprises about 5% by weight relative to the polymer, treating the mixture in a reaction tube for about 60 seconds, and applying the mixture to the tree or plant to enhance the ability thereof to absorb and retain moisture.

Abstract: A herbicidal composition, comprising: (a) at least one arylthiadiazole having the formula (I):  wherein: R represents linear or branched C1-C6 alkyl or haloalkyl; or C3-C5 cycloalkyl or halocycloalkyl; said alkyl, haloalkyl, cycloalkyl or halocycloalkyl being optionally substituted with linear or branched C1-C3 alkyl; X represents halogen; Y represents halogen; linear or branched C1-C4 alkyl or haloalkyl; linear or branched C1-C4 alkoxyl or haloalkoxyl; R1 represents hydrogen or methyl; and (b) one or more herbicidal compounds.

Abstract: The method of preparing an oxide superconducting wire comprises steps of preparing a wire by coating raw material powder for a Bi—Pb—Sr—Ca—Cu—O based oxide superconductor including a 2223 phase with a metal and heat treating the wire in a pressurized atmosphere containing oxygen in a prescribed partial pressure, and the total pressure of the pressurized atmosphere is at least 0.5 MPa. The pressure heat treatment apparatus comprises a pressure furnace storing and heat treating a target in a pressurized atmosphere, a pressure regulator for measuring the total pressure in the pressure furnace, an oxygen concentration meter for measuring the oxygen concentration in the pressure furnace and a controller for controlling the oxygen partial pressure in the pressure furnace in response to the total pressure measured by the pressure regulator and the oxygen concentration measured by the oxygen concentration meter.

Abstract: Composition of water-based drilling fluids characterized in that they comprise an oil in water emulsion.

Abstract: Herein is described a fluid that is useful in consolidating a formation without the use of a gravel pack and screen. In particular, the fluid is useful in consolidating heterogeneous formations where the permeability is not uniform over-the total formation thickness, e.g. a formation having at least a first layer and a second layer, wherein the permeability of the first layer is greater than that of the second layer. The fluid comprises at least one of a resin, a curing agent, and a surfactant, wherein the fluid is self-diverting. Optionally, a catalyst or other additives, such as an oil wetting agent, can be used. Fluids of the present invention are self-diverting, i.e.

Abstract: This invention relates to a wellbore treatment fluid and a method of enhancing wellbore treatment fluids to increase efficiency and productivity of wells. More specifically this invention provides methods for enhancing the thermal stability of wellbore treatment fluids such as drill-in, completion, work-over, packer, well treating, testing, spacer, or hole abandonment fluids. The methods include providing a wellbore treatment fluid that includes a polyol selected from glycerol, glycols and polyglycols as well as a polysaccharide viscosifier. The fluid prepared for use in this invention find particularly advantageous use as a completion fluid and as a fluid loss pill. However, the fluid can include a wide variety of additional agents to modify the physical and chemical properties of the wellbore treatment fluid.

Abstract: There are provided a highly thermal conductive grease composition having both a thermal conductivity and a satisfactory dispense property, and a cooling device applied with same. The grease composition comprises from 70 to 90% by volume of an inorganic powder which is a mixture containing at least two kinds of inorganic powders different from each other in each average particle size, and from 10 to 30% by volume of a base oil containing a mineral oil or a synthetic oil, the base oil further containing a surfactant in an amount of from 0.2 to 2.0% by weight based on the weight of the inorganic powder.

Abstract: Disclosed are lubricant compositions comprising a dispersed hydrated alkali metal borate, a polyalkylene succinic dispersant selected from a polyalkylene succinic anhydride, a mixture of polyalkylene succinic anhydrides or derivatives thereof; and a metal salt of a polyisobutenyl sulfonate. Also disclosed are methods for improving the water tolerance of a lubricant composition and methods for preparing such lubricants comprising a dispersed hydrated alkali metal borate and a dispersant mixture.

Abstract: A composition for use in removing paint from painted surfaces comprising an aqueous mixture of at least one alkoxyether solvent, a C1-C6 alcohol, at least one nitrogen containing compound, and a nonionic compound having an HLB value of 7.3 to 15.0.

Abstract: A package with a label, wherein the material of which the label, label adhesive and/or top coating is made comprises UV absorbers to protect the product's colorant dye and other organic compounds. The package may contain translucent or transparent consumer product, such as an aqueous heavy duty liquid having colorant dye. The package may itself be transparent or translucent.

Abstract: An acidic hard surface liquid detergent with desirable cleansing and antibacterial properties comprises a C8-18 anionic surfactant, nonionic surfactants, a cosurfactant, water insoluble hydrocarbon, essential oil or perfume, a hydroxy aliphatic acid and/or salicylic acid and water.

Abstract: This invention is directed to a water soluble sachet comprising a detergent composition having an encapsulated bleach. The water soluble sachet unexpectedly results in excellent cleaning properties and minimizes spot and film formation on items being cleaned in a dishwasher.

Abstract: An attractant scent and solid delivery vehicle allows the application of attractant scent or other types of scent using a solid delivery vehicle, from a convenient container similar to that used for underarm deodorant. The attractant scent is typically animal urine, but other attractant scents or other types of scents, could be substituted. Approximately 40 parts water, 30 parts urine or other attractant, and 30 parts propylene glycol are mixed in a double-jacketed container. The mixture is heated to 160 degrees. Approximately 15 parts amorphous fumed silica and 10 to 15 parts sodium sterate are then added, and the ingredients are mixed thoroughly. The mixture is then cooled to 125 degrees. The cooled mixture is then poured into containers. Preferred containers include those used for underarm deodorant. In use, the attractant scent and solid delivery vehicle may be advanced from the container and a portion of the solid applied to form a thin coating on any desired surface, such as the bottom of a boot.

Abstract: Carbonyl compounds derived from the reaction of alkyl cyclopentenols and vinyl ethers are described. The carbonyl compounds described have excellent fragrance properties, and their use as fragrances and/or fragrance-enhancing compounds is also described. Processes for the preparation of the carbonyl compounds are described as well.

Abstract: The compound according to the formula set forth below where A is B is or A and B together form the ring structure and X, R′ and R are independently H and CH3 and m=0 or 1. and the use of the compound in creating fragrances, and scents in items such as perfumes, colognes and personal care products is disclosed.

Abstract: Methods for modulating T cell responses by manipulating intracellular signals associated with T cell costimulation are disclosed. The methods involve inhibiting or stimulating the production of at least one D3-phosphoinositide in a T cell. Production of D3-phosphoinositides can be manipulated by contacting a T cell with an inhibitor or activator of phosphatidylinositol 3-kinase. Inhibitors of phosphatidylinositol 3-kinase for use in the methods of the invention include wortmannin and quercetin, or derivatives or analogues thereof. The methods of the invention can further comprise modulating other intracellular signals associated with costimulation, such as protein tyrosine phosphorylation, for example by modulating the activity of a protein tyrosine kinase or a protein tyrosine phosphatase in the T cell.

Abstract: The present invention provides substantially purified laminin 2, methods for making recombinant laminin 2, cells that express recombinant laminin 2, and methods for using the substantially purified laminin 2 to accelerate peripheral nervous system nerve regeneration, and to promote cell attachment and migration.

Abstract: The present invention relates to the design, production and use of analogs of thrombomodulin (TM) that have the ability to enhance the thrombin-mediated activation of protein C but which have a significantly reduced ability to promote activation of thrombin-activatable fibrinolysis inhibitor (TAFI). These analogs are useful in, for example, antithrombotic therapy.

Abstract: This invention concerns nematicidal proteins obtainable from Bacillus thuringiensis isolates. The subject invention also provides various methods of using these proteins for controlling nematodes.

Abstract: The present invention relates a novel immunological effect of one peptide from Limulus anti-LPS factor protein. The immunological effect are, (1) Induce an antiviral state in both the Hep-2 and MDBK cell lines, (2) Supernatant from human mononuclear cells stimulated with peptide Limulus anti-LPS factor (LALF) is able to induce antiviral effect on Hep-2 cell line by mean of IFN-&ggr; (3) LALF peptide is able to modulate the immune response in vitro and in vivo. The present invention can be used in therapeutic and/or prophylactic treatment regimens of humans and animals to enhance their immune responses, without stimulating the production of certain biochemical mediators (e.g., TNF-&agr;) that can cause detrimental effects, such as fever and inflammation.

Abstract: Compounds are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist compounds, which include peptides, are useful to increase serum and tissue levels of active IGFs in a mammal.

Abstract: The present invention provides compositions and methods for the treatment of cancer in a subject wherein compounds of Formula I as defined herein in combination with paclitaxel, taxotere or modified taxane or taxoid analogs provide enhanced anticancer effects over the effects achieved with the individual compounds.

Abstract: The present invention relates to a pharmaceutical formulation for stimulating the growth of gram-positive bacilli and increasing the acidity in the vagina which comprises sucrose and/or maltose, to the use of certain sucrose and/or maltose, in preparing the pharmaceutical formulation for stimulating the growth of gram-positive bacilli and increasing the acidity in the vagina, in particular to a method for stimulating the growth of gram-positive bacilli and increasing the acidity in the vagina, treating the reduction of gram-positive bacilli and the lowness of acidity in vagina as well as the vaginitis and the disturbance of vaginal bacterioflora accompanying the reduction of gram-positive bacilli, especially bacterial vaginal disease.

Abstract: The present invention relates to a method of treating angiogenesis in tumor conditions in a mammal suffering therefrom which comprises administering to a mammal in need thereof an effective amount of a cyclic compound selected from the group consisting of cyclopentane, cyclohexane, cycloheptane, monosaccharide, disaccharide, trisaccharide, tetrasaccharide, piperidine, tetrahydrothiopyran, 5-oxotetrahydrothiopyran, 5,5-dioxotetrahydrothiopyran, tetrahydroselenopyran, tetrahydrofuran, pyrrolidine, tetrahydrothiophene, 5-oxotetrahydrothiophene, 5,5-dioxotetrahydrothiophene, tetrahydroselenophene, benzene, cumene, mesitylene, naphthalene and phenanthrene, in which said cyclic compound is substituted by at least three vicinal phosphorus containing radicals of the formula: The present application is also directed to the use of these compounds for treating inflammatory conditions, tissue repair conditions and/or infectious conditions in a mammal.

Abstract: Methods for inhibiting angiogenisis are disclosed the comprise administering oleouropein and/or the products of its hydrolysis in therapeutically effective amounts. The methods and compositions of the present invention are particularly effective in inhibiting the vascularization of endothelial cells, and may be utilized to treat a wide variety of cancers, ocular diseases, and inflammatory conditions.

Abstract: A sealed glass container containing therein a stable, injectable, sterile, pyrogen-free doxorubicin anti-tumor composition in a solution which consists essentially of a physiologically acceptable salt of doxorubicin dissolved in a physiologically acceptable solvent therefor, wherein said solution has not been reconstituted from a lyophilizate, and wherein said solution has a pH of from 2.5-3.5 and a concentration of said doxorubicin of from 0.1 to 100 mg/ml.

Abstract: A novel strategy for monitoring the expression of a transgene in a patient is disclosed. A marker peptide is genetically fused to either the N-terminus or C-terminus of the product of a transgene through a linker peptide which bears the recognition sequence of a host cell protease. Expression of the transgene results in release of the marker peptide into extracellular body fluid of the patient in proportion to the amount of transgene product. The level of the released marker peptide serves as an indicator of the level of transgene expression. The system is particularly useful for monitoring the expression of therapeutic transgenes and production of the therapeutic gene product.

Abstract: A method and composition for inhibiting human cholesterol absorption comprising ingesting a therapeutic amount of an inhibitor of human cholesterol esterase comprising very high molecular weight sulfated polysaccharide having a sulfate to monomer ratio of from 1.0 to 3.0, containing less than about 5.0 wt. percent of sulfated polysaccharides having a molecular weight less than 75,000 Daltons, and containing less than 0.5 weight percent of inorganic sulfate.

Abstract: The application discloses esters of hyaluronic acid, wherein a first part of the carboxylic functions is esterified with an araliphatic alcohol and a second part is esterified with at least one long-chain, straight aliphatic alcohol with between 10 and 22 carbon atoms. The possible remaining non-esterified carboxylic functions, if present, are salified. The application further discloses biocompatible threads having a multifilament conformation comprising filaments formed by the aforesaid esters, and their use in the fields of medicine and surgery.

Abstract: The invention provides pharmaceutical formulation comprising voriconazole, or a pharmaceutically acceptable derivative thereof, and a sulfobutylether &bgr;-cyclodextrin.

Abstract: Compositions comprising ferrous ion and an ascorbate have a synergistic effect on cartilage development. Therapeutic compositions comprising ferrous ion and an ascorbate are therefore useful in the treatment of osteoarthritis. The addition of a glucosamine, such as glucosamine hydrochloride, to the composition has a further enhanced effect on cartilage production. Therapeutic compositions comprising ferrous ion, an ascorbate and a glucosamine derivative are even more useful in the treatment of osteoarthritis.

Abstract: A method of dyeing and treating a substrate using a water-stabilized organosilane. A method of antimicrobially treating a food article. A method of antimicrobially coating a fluid container. A method of antimicrobially coating a latex medical article.

Abstract: The invention provides methods for enhancing cognitive activity and stimulating memory capacity, comprising the step of administering an effective amount of a compound with GABAC receptor antagonist activity to an animal in need of such treatment. Preferably the compound has selective GABAc receptor antagonist activity, and more preferably comprises a phosphinic acid group. The invention also provides novel compounds and compositions. The methods of the invention are useful in the treatment of dementias and conditions involving cognitive deficit, or memory impairment.

Abstract: This invention relates to an optically active benzothiepin derivative represented by the formula: wherein R represents a lower alkyl group; R1 and R2 independently represent a lower alkyl group, or may bind together to form a ring, which exhibits excellent osteogenesis-promoting action and is useful as a prophylactic or therapeutic drug for bone diseases.

Abstract: Methods, compounds and compositions are disclosed for treating amyloidogenic diseases, like Alzheimer's disease and type 2 diabetes, and particularly prion diseases associated with conversion of protease sensitive PrP (PrP-sen) to protease resistant PrP (PrP-res), by administering therapeutically effective amounts of a tetrapyrrole. Particular disclosed tetrapyrroles having this activity include phthalocyanines, deuteroporphyrins, and meso-substituted porphines. Complexes of certain of the pyrroles with metals or metal ions produce compounds that are particularly effective in converting the conversion of PrP-sen to PrP-sen. The treatment of the present invention is particularly suited for preventing or inhibiting the progression of prion related diseases, such as transmissible spongiform encephalopathies.

Abstract: The present invention relates to compounds of the formula I: or a pharmaceutically acceptable derivative or prodrug thereof. The compounds are useful as inhibitors of bacterial gyrase activity. The present invention also relates to methods for treating bacterial infections in mammala. The present invention also relates to methods for decreasing bacterial quantity in a biological sample.

Abstract: A cyclic diamine compound of formula (1): wherein R1 and R2 are individually a hydrogen atom or a methoxy group, provided R1 is a methoxy group when R2 is a hydrogen atom, or a hydrogen atom when R2 is a methoxy group; A is an oxygen atom, a sulfur atom, CH═CH, CH═N or NR3, in which R3 is a hydrogen atom, or a lower alkyl, hydroxy lower alkyl, lower alkoxy lower alkyl, aryl or aryl lower alkyl group; B is a nitrogen atom, CH or CR4, in which R4 is a hydrogen atom, or a lower alkyl, hydroxy lower alkyl, lower alkoxy lower alkyl, aryl or aryl lower alkyl group; m is 1 or 2; and n is a number of 1 to 5, an acid-addition salt thereof, or a hydrate thereof. The compound has inhibitory effects on cell adhesion and is useful for treatment of allergy, asthma, rheumatism, arteriosclerosis, and inflammation.

Abstract: Disclosed are compounds which inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits &bgr;-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

Abstract: This invention relates to novel lactams of Formula (I): having drug and bio-affecting properties, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of A&bgr;-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to &bgr;-amyloid production such as Alzheimer's disease and Down's Syndrome.

Abstract: The invention provides compounds with antagonism against excitatory amino acid receptors, in particular, AMPA receptor having 6-substituted-7-heteroquinoxalinecarboxylic acid derivatives and addition salts thereof as effective ingredients, and processes for the preparation of both. The compounds are 6-substituted-7-heteroquinoxalinecarboxylic acid derivatives represented by the formula (1) where A denotes a single bond or methylene (CH2), Y denotes a nitrogen atom or ═CH—, V denotes a single bond or methylene (CH2), T denotes a hydroxyl group, amino group, lower alkoxycarbonyl group, carboxyl group, aldehyde group or the like, Q denotes a halogen atom, lower alkyl group or lower alkoxy group, and R1 denotes a hydroxyl group, lower alkoxy group or the like, and addition salts thereof.

Abstract: The invention is directed to physiologically active compounds of formula (I): wherein R1 represents R3—Z3—, R3—L2—R4—Z3—, R3—L3—Ar1—L4—Z3— or R3—L3—Ar1—L2—R4—Z3—; R2 represents hydrogen, halogen, lower alkyl or lower alkoxy; A1 represents a straight chain C2-3alkylene linkage optionally substituted by one or more groups chosen from alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, imino, oxo, thioxo, or alkyl substituted by —ZR6, —NY1Y2, —CO2R6 or —C(═O)—NY1Y2; L1 represents a direct bond; an alkenylene, alkylene, alkynylene, cycloalkenylene, cycloalkylene, heteroaryldiyl, heterocycloalkylene or arylene linkage each optionally substituted by (a) an acidic functional group, cyano, oxo, —S(O)mR9, R3, —C(═O)—R3, —C(═O)—OR3, —N(R8)—C(═O)—R9, —N(R8)—C(═O)—OR9, —N(R

Abstract: Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders.

Abstract: The present invention provides HIV aspartyl protease inhibitors of the formula; and when the compound of formula I comprises an amino group, pharmaceutically acceptable ammonium salts thereof, wherein n is 3 or 4, wherein R1 may be, for example, iso-butyl, wherein X and Y, same or different, may be, for example, NH2 and F, and wherein R2 and R3 are as defined herein.

Abstract: The invention relates to novel fluoromethoximino compounds, to a process for their preparation and to their use as pesticides, and also to novel intermediates and to a plurality of processes for their preparation.

Abstract: The present invention is directed to piperazine-containing macrocyclic compounds which inhibit prenylyl-protein transferase, such as farnesyl-protein transferase (FTase), and therefore inhibit the prenylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting prenyl-protein transferase and the prenylation of the oncogene protein Ras.

Abstract: The invention comprises compounds of the class of azaindole piperazine diamide derivatives, compositions thereof and their use as anti-viral agents, and particularly for treating HIV infection.

Abstract: A pyrimidine derivative of formula (I) wherein, for example, R1 is-(1-6C)alkyl or (3-5C)alkenyl [optionally substituted by a phenyl substituent]; Q1 and Q2 are independently selected from phenyl, naphthyl, indanyl and 1,2,3,4-tetrahydronaphthyl; and one or both of Q1 and Q2 bears one substituent of formula (Ia) [provided that when present in Q1 the substituent of formula (Ia) is not adjacent to the —NH-link]; wherein, for example, X is CH2, O, S or NH; Y is H or as defined for Z; Z is OH, SH, NH2, (1-4C)alkoxy, (1-4C)alkylthio, —NH(1-4C)alkyl, —N[(1-4C)alkyl]2 or —NH-(3-8C)cycloalkyl; n is 1, 2 or 3; m is 1, 2 or 3; and Q1 and Q2 may each optionally bear other substituents selected from halogeno, (1-6C)alkyl, cyano and (2-4C)alkenyl, or a pharmaceutically-acceptable salt, or in-vivo-hydrolysable ester thereof; are useful as anti-cancer agents; and processes for their manufacture and pharmaceutical compositions containing them are describe